A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseStephen Salloway, Paul Aisen, Anne M. Fagan et al.|Nature Medicine|2021Cited by 365
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer diseaseEric McDade, Robert A. Koeppe, Guoqiao Wang et al.|Neurology|2018Cited by 322
Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s diseaseErik C. B. Johnson, Yudy Milena Leon, Shijia Bian et al.|Nature Medicine|2023Cited by 172
Amyloid‐Related Imaging Abnormalities in the <scp>DIAN‐TU</scp>‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph‐Mathurin, Richard J. Perrin, Jorge J. Llibre‐Guerra et al.|Annals of Neurology|2022Cited by 42
Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer DiseaseJorge J. Llibre‐Guerra, Eric McDade, Yan Li et al.|JAMA Network Open|2019Cited by 40